111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
姜黄素纳米药物递送系统的构建策略及其在溃疡性结肠炎治疗中的应用
Authors Ning H , Huang X, Lin X , Sun Q, Zheng Y, Deng N, Xu Y
Received 13 October 2025
Accepted for publication 5 December 2025
Published 16 December 2025 Volume 2025:20 Pages 15135—15166
DOI https://doi.org/10.2147/IJN.S573966
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. RDK Misra
Hang Ning,1,* Xinyu Huang,1,* Xiaoyuan Lin,1,* Qifang Sun,1 Yuchen Zheng,1 Na Deng,2 Yin Xu1
1Gastroenterology department, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People’s Republic of China; 2School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Na Deng, School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, 300 Xue Shl Road, Sclence & Education Park, YueLu District, Changsha, Hunan, 410208, People’s Republic of China, Tel +86-13548615590, Email 243671178@qq.com Yin Xu, Gastroenterology department, The First Hospital of Hunan University of Chinese Medicine, No. 95 Shaoshan Middle Road, Yuhua District, Changsha, Hunan, 410007, People’s Republic of China, Tel +86-13787262655, Email 311118@hnucm.edu.cn
Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a continuously increasing incidence worldwide. The existing treatment options are limited due to low drug bioavailability and systemic side effects. Natural products, such as curcumin, have emerged as potential effective drugs for UC treatment due to their multi-target and multi-mechanism therapeutic advantages. However, the clinical trial and experimental research results of curcumin show a contrast due to its own physicochemical limitations (low solubility, low bioavailability, etc). gastrointestinal digestion factors (pH, digestive enzymes, etc). and the combined limitations of the colonic intestinal barrier (intestinal flora, mucus barrier, intestinal epithelial barrier, etc). The clinical translation is thus hindered. The Nano-Drug Delivery System (NDDS) uses size control, surface functionalization, and intelligent stimulus-responsive design to transform the factors that limit curcumin absorption and utilization into delivery targets, constructing pH-dependent, gut flora-dependent, receptor-dependent, etc. NDDS, achieving improved drug solubility, enhanced absorption, controlled release, and targeted delivery, significantly enhancing the therapeutic effect of curcumin for UC. This review focuses on the pathophysiology of UC and uniquely systematically analyzes the construction logic of natural product NDDS from the perspective of the above biological barriers, clarifying the applicable scenarios and core advantages of various strategies. At the same time, this article also discusses the key challenges faced by the clinical translation of NDDS, including the toxicity risk caused by enhanced drug absorption, the safety of the carrier itself, and the transformation obstacles caused by species receptor spectrum differences etc. as well as an important point to recognize is that there is still a considerable distance to the clinical translation of NDDS. In summary, NDDS brings broad prospects for the clinical application of natural products, but the current research level is far from meeting the needs of clinical translation. Future design must deeply align with the pathological characteristics of UC to promote its transition from the laboratory to clinical application.
Keywords: ulcerative colitis, curcumin, nano-drug delivery system, natural products
1Gastroenterology department, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, People’s Republic of China; 2School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Na Deng, School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, 300 Xue Shl Road, Sclence & Education Park, YueLu District, Changsha, Hunan, 410208, People’s Republic of China, Tel +86-13548615590, Email 243671178@qq.com Yin Xu, Gastroenterology department, The First Hospital of Hunan University of Chinese Medicine, No. 95 Shaoshan Middle Road, Yuhua District, Changsha, Hunan, 410007, People’s Republic of China, Tel +86-13787262655, Email 311118@hnucm.edu.cn
Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a continuously increasing incidence worldwide. The existing treatment options are limited due to low drug bioavailability and systemic side effects. Natural products, such as curcumin, have emerged as potential effective drugs for UC treatment due to their multi-target and multi-mechanism therapeutic advantages. However, the clinical trial and experimental research results of curcumin show a contrast due to its own physicochemical limitations (low solubility, low bioavailability, etc). gastrointestinal digestion factors (pH, digestive enzymes, etc). and the combined limitations of the colonic intestinal barrier (intestinal flora, mucus barrier, intestinal epithelial barrier, etc). The clinical translation is thus hindered. The Nano-Drug Delivery System (NDDS) uses size control, surface functionalization, and intelligent stimulus-responsive design to transform the factors that limit curcumin absorption and utilization into delivery targets, constructing pH-dependent, gut flora-dependent, receptor-dependent, etc. NDDS, achieving improved drug solubility, enhanced absorption, controlled release, and targeted delivery, significantly enhancing the therapeutic effect of curcumin for UC. This review focuses on the pathophysiology of UC and uniquely systematically analyzes the construction logic of natural product NDDS from the perspective of the above biological barriers, clarifying the applicable scenarios and core advantages of various strategies. At the same time, this article also discusses the key challenges faced by the clinical translation of NDDS, including the toxicity risk caused by enhanced drug absorption, the safety of the carrier itself, and the transformation obstacles caused by species receptor spectrum differences etc. as well as an important point to recognize is that there is still a considerable distance to the clinical translation of NDDS. In summary, NDDS brings broad prospects for the clinical application of natural products, but the current research level is far from meeting the needs of clinical translation. Future design must deeply align with the pathological characteristics of UC to promote its transition from the laboratory to clinical application.
Keywords: ulcerative colitis, curcumin, nano-drug delivery system, natural products